Last reviewed · How we verify
GM-CSF group
GM-CSF (granulocyte-macrophage colony-stimulating factor) stimulates the production and activation of granulocytes and macrophages to enhance immune response.
GM-CSF (granulocyte-macrophage colony-stimulating factor) stimulates the production and activation of granulocytes and macrophages to enhance immune response. Used for Cancer immunotherapy (Phase 3 indication not fully specified).
At a glance
| Generic name | GM-CSF group |
|---|---|
| Also known as | GM-CSF |
| Sponsor | Centre for Endocrinology and Reproductive Medicine, Italy |
| Drug class | Cytokine |
| Target | GM-CSF receptor (CD116/CD131) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GM-CSF is a cytokine that acts on hematopoietic progenitor cells to promote the differentiation and proliferation of granulocytes and macrophages. By increasing these immune cell populations and enhancing their functional activity, GM-CSF can boost innate and adaptive immune responses. This mechanism is leveraged therapeutically in cancer immunotherapy and to support immune recovery in various clinical contexts.
Approved indications
- Cancer immunotherapy (Phase 3 indication not fully specified)
Common side effects
- Fever
- Fatigue
- Bone pain
- Injection site reactions
- Elevated liver enzymes
Key clinical trials
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (PHASE2)
- Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (PHASE1)
- Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma (PHASE1, PHASE2)
- Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (PHASE1)
- Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (PHASE1)
- Fatty Liver and Pancreatic Steatosis
- Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma (PHASE2)
- A Trial of FANG™ Vaccine for Participants With Ovarian Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |